{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:26:58Z","timestamp":1790980018945,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100019533","name":"Science Fund for Distinguished Young Scholars of Fujian Province","doi-asserted-by":"publisher","award":["No. 2021J01761"],"award-info":[{"award-number":["No. 2021J01761"]}],"id":[{"id":"10.13039\/501100019533","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Funds for the Innovation of Science and Technology of Fujian Province","award":["No. 2021Y9038"],"award-info":[{"award-number":["No. 2021Y9038"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81673510 and 82073936"],"award-info":[{"award-number":["No. 81673510 and 82073936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Outstanding Scientific Fund of Shengjing Hospital","award":["No. M0779"],"award-info":[{"award-number":["No. M0779"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00228-024-03665-x","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T15:02:26Z","timestamp":1710774146000},"page":"965-982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-6098","authenticated-orcid":false,"given":"Yu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-8028","authenticated-orcid":false,"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"8","key":"3665_CR1","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/ijc.30214","volume":"139","author":"Z Pan","year":"2016","unstructured":"Pan Z, Yang G, He H, Zhao G, Yuan T, Li Y, Shi W, Gao P, Dong L, Li Y (2016) Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study. Int J Cancer 139(8):1864\u20131872. https:\/\/doi.org\/10.1002\/ijc.30214","journal-title":"Int J Cancer"},{"key":"3665_CR2","doi-asserted-by":"publisher","first-page":"113074","DOI":"10.1016\/j.biopha.2022.113074","volume":"150","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Hua Z, Luo X, Li Y, Yu L, Li M, Lu C, Zhao T, Liu Y (2022) Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother = Biomed Pharmacother 150:113074. https:\/\/doi.org\/10.1016\/j.biopha.2022.113074","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"issue":"6","key":"3665_CR3","first-page":"456","volume":"52","author":"J Sterba","year":"2005","unstructured":"Sterba J, Val\u00edk D, Bajciov\u00e1 V, Kadlecov\u00e1 V, Gregorov\u00e1 V, Mendelov\u00e1 D (2005) High-dose methotrexate and\/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Neoplasma 52(6):456\u2013463","journal-title":"Neoplasma"},{"issue":"5","key":"3665_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1592\/phco.25.5.748.63584","volume":"25","author":"E Mantadakis","year":"2005","unstructured":"Mantadakis E, Cole PD, Kamen BA (2005) High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy 25(5):748\u2013755. https:\/\/doi.org\/10.1592\/phco.25.5.748.63584","journal-title":"Pharmacotherapy"},{"issue":"8","key":"3665_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/08880010050211321","volume":"17","author":"PJ Moe","year":"2000","unstructured":"Moe PJ, Holen A (2000) High-dose methotrexate in childhood all. Pediatr Hematol Oncol 17(8):615\u2013622. https:\/\/doi.org\/10.1080\/08880010050211321","journal-title":"Pediatr Hematol Oncol"},{"issue":"17","key":"3665_CR6","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1002\/cncr.33609","volume":"127","author":"HTK Nguyen","year":"2021","unstructured":"Nguyen HTK, Terao MA, Green DM, Pui CH, Inaba H (2021) Testicular involvement of acute lymphoblastic leukemia in children and adolescents: diagnosis, biology, and management. Cancer 127(17):3067\u20133081. https:\/\/doi.org\/10.1002\/cncr.33609","journal-title":"Cancer"},{"issue":"12","key":"3665_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21(12):1471\u20131482. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"issue":"6","key":"3665_CR8","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","volume":"84","author":"S Kawakatsu","year":"2019","unstructured":"Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, Capparelli EV (2019) Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol 84(6):1339\u20131348. https:\/\/doi.org\/10.1007\/s00280-019-03966-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3665_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bcp.14160","volume":"86","author":"JC Panetta","year":"2020","unstructured":"Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, Patel YT, Onar-Thomas A, Campagne O, Ward DA, Broniscer A, Robinson G, Gajjar A, Stewart CF (2020) Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. Br J Clin Pharmacol 86(2):362\u2013371. https:\/\/doi.org\/10.1111\/bcp.14160","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"3665_CR10","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","volume":"36","author":"LN Toksvang","year":"2022","unstructured":"Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K (2022) Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia 36(7):1749\u20131758. https:\/\/doi.org\/10.1038\/s41375-022-01591-4","journal-title":"Leukemia"},{"key":"3665_CR11","doi-asserted-by":"publisher","unstructured":"Gao X, Qian XW, Zhu XH, Yu Y, Miao H, Meng JH, Jiang JY, Wang HS, Zhai XW (2021) Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric patients with Acute Lymphoblastic Leukemia. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.701452","DOI":"10.3389\/fphar.2021.701452"},{"issue":"4","key":"3665_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jcph.1349","volume":"59","author":"KH Hui","year":"2019","unstructured":"Hui KH, Chu HM, Fong PS, Cheng WTF, Lam TN (2019) Population Pharmacokinetic Study and Individual Dose adjustments of high-dose methotrexate in Chinese Pediatric patients with Acute Lymphoblastic Leukemia or Osteosarcoma. J Clin Pharmacol 59(4):566\u2013577. https:\/\/doi.org\/10.1002\/jcph.1349","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"3665_CR13","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00277-016-2795-7","volume":"95","author":"SN Reiss","year":"2016","unstructured":"Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Douer D (2016) Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol 95(12):2009\u20132015. https:\/\/doi.org\/10.1007\/s00277-016-2795-7","journal-title":"Ann Hematol"},{"issue":"1","key":"3665_CR14","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1208\/ps040104","volume":"4","author":"PJ McNamara","year":"2002","unstructured":"McNamara PJ, Alcorn J (2002) Protein binding predictions in infants. AAPS PharmSci 4(1):E4. https:\/\/doi.org\/10.1208\/ps040104","journal-title":"AAPS PharmSci"},{"issue":"1","key":"3665_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/08880019009034317","volume":"7","author":"JD Borsi","year":"1990","unstructured":"Borsi JD, Sagen E, Romslo I, Moe PJ (1990) Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology. Pediatr Hematol Oncol 7(1):13\u201333. https:\/\/doi.org\/10.3109\/08880019009034317","journal-title":"Pediatr Hematol Oncol"},{"key":"3665_CR16","doi-asserted-by":"publisher","unstructured":"Strawn JR, Poweleit EA, Mills JA, Schroeder HK, Neptune ZA, Specht AM, Farrow JE, Zhang X, Martin LJ, Ramsey LB (2021) Pharmacogenetically guided Escitalopram Treatment for Pediatric anxiety disorders: protocol for a double-blind Randomized Trial. J Personalized Med 11(11). https:\/\/doi.org\/10.3390\/jpm11111188","DOI":"10.3390\/jpm11111188"},{"issue":"1","key":"3665_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-014-2614-6","volume":"75","author":"KD Wright","year":"2015","unstructured":"Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr., Ward D, Gajjar A, Stewart CF (2015) Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol 75(1):27\u201335. https:\/\/doi.org\/10.1007\/s00280-014-2614-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3665_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0010-4809(72)90051-1","volume":"5","author":"LB Sheiner","year":"1972","unstructured":"Sheiner LB, Rosenberg B, Melmon KL (1972) Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res Int J 5(5):411\u2013459. https:\/\/doi.org\/10.1016\/0010-4809(72)90051-1","journal-title":"Comput Biomed Res Int J"},{"issue":"12","key":"3665_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","volume":"7","author":"RJ Keizer","year":"2018","unstructured":"Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S (2018) Model-informed Precision Dosing at the Bedside: Scientific challenges and opportunities. CPT: Pharmacometrics Syst Pharmacol 7(12):785\u2013787. https:\/\/doi.org\/10.1002\/psp4.12353","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"3665_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bcp.12233","volume":"79","author":"SB Duffull","year":"2015","unstructured":"Duffull SB, Wright DF (2015) What do we learn from repeated population analyses? Br J Clin Pharmacol 79(1):40\u201347. https:\/\/doi.org\/10.1111\/bcp.12233","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3665_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13318-021-00737-6","volume":"47","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Sun L, Chen X, Zhao L, Wang X, Zhao Z, Mei S (2022) A systematic review of population pharmacokinetic models of methotrexate. Eur J Drug Metab Pharmacokinet 47(2):143\u2013164. https:\/\/doi.org\/10.1007\/s13318-021-00737-6","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3665_CR22","doi-asserted-by":"publisher","unstructured":"Wang S, Yin Q, Yang M, Cheng Z, Xie F (2023) External evaluation of population pharmacokinetic models of methotrexate for model-informed precision dosing in pediatric patients with acute lymphoid leukemia. Pharmaceutics 15(2). https:\/\/doi.org\/10.3390\/pharmaceutics15020569","DOI":"10.3390\/pharmaceutics15020569"},{"key":"3665_CR23","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical Res ed) 350:g7647. https:\/\/doi.org\/10.1136\/bmj.g7647","journal-title":"BMJ (Clinical Res ed)"},{"issue":"7","key":"3665_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Edwards S, Ensom MH, Foster DR, Hardy B, Kiser TH, la Porte C, Roberts JA, Shulman R, Walker S, Zelenitsky S, Moher D (2015) Reporting guidelines for clinical pharmacokinetic studies: the ClinPK Statement. Clin Pharmacokinet 54(7):783\u2013795. https:\/\/doi.org\/10.1007\/s40262-015-0236-8","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3665_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40262-013-0114-1","volume":"53","author":"KM Jamsen","year":"2014","unstructured":"Jamsen KM, McLeay SC, Barras MA, Green B (2014) Reporting a population pharmacokinetic-pharmacodynamic study: a journal\u2019s perspective. Clin Pharmacokinet 53(2):111\u2013122. https:\/\/doi.org\/10.1007\/s40262-013-0114-1","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3665_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-020-00963-2","volume":"60","author":"ZR Li","year":"2021","unstructured":"Li ZR, Wang CY, Zhu X, Jiao Z (2021) Population Pharmacokinetics of Levetiracetam: a systematic review. Clin Pharmacokinet 60(3):305\u2013318. https:\/\/doi.org\/10.1007\/s40262-020-00963-2","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3665_CR27","doi-asserted-by":"publisher","first-page":"e46015","DOI":"10.1371\/journal.pone.0046015","volume":"7","author":"H R\u00fchs","year":"2012","unstructured":"R\u00fchs H, Becker A, Drescher A, Panetta JC, Pui CH, Relling MV, Jaehde U (2012) Population PK\/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia. PLoS ONE 7(9):e46015. https:\/\/doi.org\/10.1371\/journal.pone.0046015","journal-title":"PLoS ONE"},{"issue":"7","key":"3665_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40262-018-00734-0","volume":"58","author":"RJ Beechinor","year":"2019","unstructured":"Beechinor RJ, Thompson PA, Hwang MF, Vargo RC, Bomgaars LR, Gerhart JG, Dreyer ZE, Gonzalez D (2019) The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the children\u2019s Oncology Group. Clin Pharmacokinet 58(7):899\u2013910. https:\/\/doi.org\/10.1007\/s40262-018-00734-0","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3665_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/jcph.1799","volume":"61","author":"E Orgel","year":"2021","unstructured":"Orgel E, Nabais T, Douglas C, Mittelman SD, Neely M (2021) Effect of body fat on population pharmacokinetics of high-dose methotrexate in pediatric patients with acute lymphoblastic leukemia. J Clin Pharmacol 61(6):755\u2013762. https:\/\/doi.org\/10.1002\/jcph.1799","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"3665_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/cpt.1957","volume":"108","author":"ZL Taylor","year":"2020","unstructured":"Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, Felicelli N, Vinks AA, Heldrup J, Ramsey LB (2020) MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase. Clin Pharmacol Ther 108(3):635\u2013643. https:\/\/doi.org\/10.1002\/cpt.1957","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3665_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/bdd.2221","volume":"41","author":"ZY Shi","year":"2020","unstructured":"Shi ZY, Liu YO, Gu HY, Xu XQ, Yan C, Yang XY, Yan D (2020) Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma. Biopharm Drug Dispos 41(3):101\u2013110. https:\/\/doi.org\/10.1002\/bdd.2221","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"3665_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/00498254.2022.2069060","volume":"52","author":"M Zhan","year":"2022","unstructured":"Zhan M, Sun Y, Zhou F, Wang H, Chen Z, Yan L, Li X (2022) Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma. Xenobiotica 52(3):265\u2013273. https:\/\/doi.org\/10.1080\/00498254.2022.2069060","journal-title":"Xenobiotica"},{"issue":"5","key":"3665_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1472-8206.1999.tb00366.x","volume":"13","author":"F Odoul","year":"1999","unstructured":"Odoul F, Le Guellec C, Lamagn\u00e8re JP, Breilh D, Saux MC, Paintaud G, Autret-Leca E (1999) Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundam Clin Pharmacol 13(5):595\u2013604. https:\/\/doi.org\/10.1111\/j.1472-8206.1999.tb00366.x","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"3665_CR34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","volume":"45","author":"D Aumente","year":"2006","unstructured":"Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garc\u00eda MJ (2006) Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 45(12):1227\u20131238. https:\/\/doi.org\/10.2165\/00003088-200645120-00007","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3665_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00280-006-0394-3","volume":"60","author":"C Plard","year":"2007","unstructured":"Plard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rieutord A, Jacqz-Aigrain E (2007) A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 60(4):609\u2013620. https:\/\/doi.org\/10.1007\/s00280-006-0394-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3665_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/FTD.0b013e3181945624","volume":"31","author":"H Colom","year":"2009","unstructured":"Colom H, Farr\u00e9 R, Soy D, Peraire C, Cendros JM, Pardo N, Torrent M, Domenech J, Mangues MA (2009) Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma. Ther Drug Monit 31(1):76\u201385. https:\/\/doi.org\/10.1097\/FTD.0b013e3181945624","journal-title":"Ther Drug Monit"},{"issue":"7","key":"3665_CR37","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3324\/haematol.2009.019778","volume":"95","author":"TD Buitenkamp","year":"2010","unstructured":"Buitenkamp TD, Math\u00f4t RA, de Haas V, Pieters R, Zwaan CM (2010) Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 95(7):1106\u20131113. https:\/\/doi.org\/10.3324\/haematol.2009.019778","journal-title":"Haematologica"},{"issue":"10","key":"3665_CR38","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"B Faganel Kotnik","year":"2011","unstructured":"Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dol\u017ean V, Jazbec J (2011) Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 67(10):993\u20131006. https:\/\/doi.org\/10.1007\/s00228-011-1046-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3665_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pbc.22999","volume":"57","author":"P J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson P, Sk\u00e4rby T, Heldrup J, Schr\u00f8der H, H\u00f6glund P (2011) High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation. Pediatr Blood Cancer 57(1):41\u201346. https:\/\/doi.org\/10.1002\/pbc.22999","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"3665_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00280-019-03977-1","volume":"85","author":"SE Medellin-Garibay","year":"2020","unstructured":"Medellin-Garibay SE, Hern\u00e1ndez-Villa N, Correa-Gonz\u00e1lez LC, Morales-Barrag\u00e1n MN, Valero-Rivera KP, Res\u00e9ndiz-Galv\u00e1n JE, Ortiz-Zamudio JJ, Mil\u00e1n-Segovia RDC, Romano-Moreno S (2020) Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 85(1):21\u201331. https:\/\/doi.org\/10.1007\/s00280-019-03977-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3665_CR41","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1742-7843.2009.00533.x","volume":"106","author":"L Aarons","year":"2010","unstructured":"Aarons L, Ogungbenro K (2010) Optimal design of pharmacokinetic studies. Basic Clin Pharmacol Toxicol 106(3):250\u2013255. https:\/\/doi.org\/10.1111\/j.1742-7843.2009.00533.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"3665_CR42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/ftd.0000000000000434","volume":"39","author":"MD Aumente","year":"2017","unstructured":"Aumente MD, L\u00f3pez-Santamar\u00eda J, Donoso-Rengifo MC, Reyes-Torres I, Montejano Herv\u00e1s P (2017) Evaluation of the Novel Methotrexate Architect Chemiluminescent Immunoassay: clinical impact on pharmacokinetic monitoring. Ther Drug Monit 39(5):492\u2013498. https:\/\/doi.org\/10.1097\/ftd.0000000000000434","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3665_CR43","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/ftd.0000000000000085","volume":"36","author":"E den Boer","year":"2014","unstructured":"den Boer E, Koch BC, Huisman R, de Jonge R (2014) Using fluorescence polarization immunoassay for determination of erythrocyte methotrexate polyglutamates, a quick and easy test? Ther Drug Monit 36(6):819\u2013823. https:\/\/doi.org\/10.1097\/ftd.0000000000000085","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3665_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2116\/analsci.33.665","volume":"33","author":"S Mei","year":"2017","unstructured":"Mei S, Zhu L, Li X, Wang J, Jiang X, Chen H, Huo J, Yang L, Lin S, Zhao Z (2017) UPLC-MS\/MS Analysis of Methotrexate in Human plasma and comparison with the fluorescence polarization immunoassay. Anal Sciences: Int J Japan Soc Anal Chem 33(6):665\u2013670. https:\/\/doi.org\/10.2116\/analsci.33.665","journal-title":"Anal Sciences: Int J Japan Soc Anal Chem"},{"issue":"10","key":"3665_CR45","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3109\/10428194.2012.676177","volume":"53","author":"M Joerger","year":"2012","unstructured":"Joerger M, Huitema AD, Illerhaus G, Ferreri AJ (2012) Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 53(10):1867\u20131875. https:\/\/doi.org\/10.3109\/10428194.2012.676177","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3665_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00280-002-0512-9","volume":"50","author":"J Li","year":"2002","unstructured":"Li J, Gwilt P (2002) The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 50(5):373\u2013382. https:\/\/doi.org\/10.1007\/s00280-002-0512-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"3665_CR47","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00280-006-0388-1","volume":"59","author":"PA Thompson","year":"2007","unstructured":"Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, Camitta BM, Dreyer ZE, Bomgaars LR (2007) Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 59(6):847\u2013853. https:\/\/doi.org\/10.1007\/s00280-006-0388-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 1","key":"3665_CR48","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1002\/jcph.1497","volume":"59","author":"I Ince","year":"2019","unstructured":"Ince I, Solodenko J, Frechen S, Dallmann A, Niederalt C, Schlender J, Burghaus R, Lippert J, Willmann S (2019) Predictive Pediatric modeling and Simulation using Ontogeny Information. J Clin Pharmacol 59(Suppl 1):S95\u2013s103. https:\/\/doi.org\/10.1002\/jcph.1497","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3665_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/psp4.12883","volume":"12","author":"X Zhou","year":"2023","unstructured":"Zhou X, Dun J, Chen X, Xiang B, Dang Y, Cao D (2023) Predicting the correct dose in children: role of computational Pediatric physiological-based pharmacokinetics modeling tools. CPT: Pharmacometrics Syst Pharmacol 12(1):13\u201326. https:\/\/doi.org\/10.1002\/psp4.12883","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"3665_CR50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"3665_CR51","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00467-017-3693-5","volume":"32","author":"VE Millisor","year":"2017","unstructured":"Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF (2017) Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nephrol 32(9):1575\u20131584. https:\/\/doi.org\/10.1007\/s00467-017-3693-5","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"3665_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00280-002-0552-1","volume":"51","author":"T Sk\u00e4rby","year":"2003","unstructured":"Sk\u00e4rby T, J\u00f6nsson P, Hjorth L, Behrentz M, Bj\u00f6rk O, Forestier E, Jarfelt M, L\u00f6nnerholm G, H\u00f6glund P (2003) High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 51(4):311\u2013320. https:\/\/doi.org\/10.1007\/s00280-002-0552-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"3665_CR53","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1146\/annurev.me.39.020188.002341","volume":"39","author":"AS Levey","year":"1988","unstructured":"Levey AS, Perrone RD, Madias NE (1988) Serum creatinine and renal function. Annu Rev Med 39:465\u2013490. https:\/\/doi.org\/10.1146\/annurev.me.39.020188.002341","journal-title":"Annu Rev Med"},{"key":"3665_CR54","doi-asserted-by":"publisher","unstructured":"Houlind MB, Petersen KK, Palm H, J\u00f8rgensen LM, Aakj\u00e6r M, Christrup LL, Petersen J, Andersen O, Treldal C (2018) Creatinine-based renal function estimates and dosage of postoperative Pain Management for Elderly Acute hip fracture patients. Pharmaceuticals (Basel Switzerland) 11(3). https:\/\/doi.org\/10.3390\/ph11030088","DOI":"10.3390\/ph11030088"},{"issue":"6","key":"3665_CR55","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s0022-3476(84)80479-5","volume":"104","author":"GJ Schwartz","year":"1984","unstructured":"Schwartz GJ, Feld LG, Langford DJ (1984) A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 104(6):849\u2013854. https:\/\/doi.org\/10.1016\/s0022-3476(84)80479-5","journal-title":"J Pediatr"},{"key":"3665_CR56","doi-asserted-by":"publisher","unstructured":"Taylor ZL, Vang J, Lopez-Lopez E, Oosterom N, Mikkelsen T, Ramsey LB (2021) Systematic review of pharmacogenetic factors that Influence High-Dose Methotrexate Pharmacokinetics in Pediatric malignancies. Cancers 13(11). https:\/\/doi.org\/10.3390\/cancers13112837","DOI":"10.3390\/cancers13112837"},{"issue":"3","key":"3665_CR57","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00228-013-1623-4","volume":"70","author":"S Kodidela","year":"2014","unstructured":"Kodidela S, Suresh Chandra P, Dubashi B (2014) Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level? Eur J Clin Pharmacol 70(3):253\u2013260. https:\/\/doi.org\/10.1007\/s00228-013-1623-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3665_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40262-020-00937-4","volume":"60","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Wang CY, Li ZR, Pan Y, Liu MB, Jiao Z (2021) Can Population Pharmacokinetics of Antibiotics be extrapolated? Implications of external evaluations. Clin Pharmacokinet 60(1):53\u201368. https:\/\/doi.org\/10.1007\/s40262-020-00937-4","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3665_CR59","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/imj.13412","volume":"47","author":"J Donagher","year":"2017","unstructured":"Donagher J, Martin JH, Barras MA (2017) Individualised medicine: why we need bayesian dosing. Intern Med J 47(5):593\u2013600. https:\/\/doi.org\/10.1111\/imj.13412","journal-title":"Intern Med J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03665-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03665-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03665-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T03:32:22Z","timestamp":1717731142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03665-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["3665"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03665-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"16 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}